STTK Shattuck Labs, Inc.

CIK 0001680367 45 ready 8-Ks latest August 11, 2026, 6:59 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 45

Latest filing August 11, 2026, 6:59 AM ET

Top materiality 0.85

Event mix earnings ×20 · other_material ×18 · other ×4

Sentiment 13 pos · 3 neg · 29 neu

Latest earnings reported 2026-Q2

Executive change recent →

Recent 8-K filings for STTK

Highest-materiality recent filing

Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial

December 13, 2023, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.
27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.

Read filing →

August 11, 2026, 6:59 AM ET earnings materiality 0.75 positive item 2.02 item 9.01

Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive

Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.
June 11, 2026, 8:25 AM ET other material materiality 0.65 neutral item 1.01 item 9.01 ◈ Material Agreements

Shattuck Labs raises ~$86.25M in underwritten public offering of common stock and pre-funded warrants

Offered 10,879,376 shares at $4.00/share and 7,870,624 pre-funded warrants at $3.9999 each.
June 9, 2026, 4:28 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.

Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.
March 5, 2026, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026

Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.
January 22, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Shattuck Labs enters $75M ATM equity distribution agreement with Leerink Partners

Entered Sales Agreement with Leerink Partners for at-the-market offering of up to $75M of common stock.
November 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement

First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement

First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.
August 26, 2025, 7:59 PM ET other material materiality 0.75 positive item 5.02 item 7.01 item 9.01

Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029

Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.
August 14, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement

Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.
August 5, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials

Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
May 1, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025

Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.
March 27, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1

Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.
November 14, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027

Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).
October 1, 2024, 7:59 PM ET other material materiality 0.80 negative item 1.02 item 2.05 item 8.01 item 9.01 ◈ Restructurings & Charges

Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325

Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.
August 1, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial

Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.
June 14, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B

Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.
March 4, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors

Appointments effective March 1, 2024; board now includes two new independent directors.
February 29, 2024, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M

Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.
February 13, 2024, 6:59 PM ET other material materiality 0.65 positive item 1.01 ◈ Material Agreements

Shattuck Labs and Ono Pharma collaborate on fusion proteins; upfront $9M, milestones up to $217.5M

Upfront payment plus research milestones total up to $9M; Ono reimburses all research costs.
December 22, 2023, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements ×3

Shattuck Labs raises ~$47.5M in public offering and private placement of pre-funded warrants

Public offering of 4,651,163 common shares at $6.45/share; private placement of pre-funded warrants for 3,100,823 shares at $6.4499/warrant.
December 21, 2023, 6:59 PM ET other material materiality 0.60 neutral item 8.01

Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML

HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.
December 13, 2023, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial

79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.
November 9, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Shattuck reports Q3 net loss $27.5M; SL-172154 PROC ORR ~27% vs 4% benchmark

Net loss of $27.5M ($0.65/share) for Q3 2023 vs $24.6M ($0.58/share) a year ago.
August 10, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs Q2 net loss $21.3M ($0.50/sh); cash $117.2M; SL-172154 trials advancing

Cash and investments $117.2M at June 30, 2023, down from $214.2M a year earlier; runway through end of 2024.
February 23, 2023, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs reports Q4 2022 net loss of $25.4M, discontinues SL-279252 program

Net loss Q4 2022 $25.4M ($0.60/share) vs net income $7.8M in Q4 2021; full-year net loss $101.9M.
November 8, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete

Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.
March 15, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252

Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.
November 9, 2021, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated

Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.
August 11, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Shattuck Labs reports Q2 net loss of $23.6M; pipeline advances with SL-172154 and SL-279252

Net loss $23.6M ($0.56 loss per share) vs $6.2M ($0.81 loss per share) in Q2 2020; revenue negative $4.2M due to Takeda collaboration cost changes.

Executive changes

Appointed

Dr. Clay Siegall

Class III director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Appointed

Dr. Kate Sasser

Class II director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Departed

Josiah Hornblower

Chairman of the Board

STTK · Shattuck Labs, Inc.

Effective: 2021-10-22
Successor: George Golumbeski
Filed: October 28, 2021, 7:59 PM ET

On October 22, 2021, Josiah Hornblower notified the board of directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) of his intent to resign as a director and Chairman of the Board, effective as of such date.

Appointed

Dr. Carrie Brownstein

Director

STTK · Shattuck Labs, Inc.

Effective: 2021-10-22
Filed: October 28, 2021, 7:59 PM ET

On October 22, 2021, the Board appointed Dr. Carrie Brownstein as a member of the Board, effective immediately.

Role change

George Golumbeski

Chairman of the Board

STTK · Shattuck Labs, Inc.

Effective: 2021-10-22
Filed: October 28, 2021, 7:59 PM ET

The Board appointed independent director George Golumbeski to replace Mr. Hornblower as Chairman of the Board.

Earnings & guidance

2026-Q2 EPS reported -$0.25 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

13 positive 3 negative 29 neutral

source · STTK on sec.gov